MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 500M 1B 1.5B Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 14.6M Q3 '24: 76.8M Q4 '24: 180.1M Q1 '25: 317.4M Q2 '25: 515.5M Q3 '25: 740.6M Q4 '25: 958.4M Q1 '26: 1.1B Q2 '26: 1.3B Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 400M 800M 1.2B Q4 '23: 0 Q1 '24: 0 Q2 '24: 14M Q3 '24: 74M Q4 '24: 173.9M Q1 '25: 306.6M Q2 '25: 496.4M Q3 '25: 705.5M Q4 '25: 902.3M Q1 '26: 1.1B Q2 '26: 1.2B Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q1 '16: -31.5M Q2 '16: -14.6M Q3 '16: -27.8M Q4 '16: -25.2M Q1 '17: -30.6M Q2 '17: -36.4M Q3 '17: -30.9M Q4 '17: -32.1M Q1 '18: -33.1M Q2 '18: -32.4M Q3 '18: -35.1M Q4 '18: -40.7M Q1 '19: -51.7M Q2 '19: -66.6M Q3 '19: -79.5M Q4 '19: -95M Q3 '20: -177.1M Q4 '20: -206.7M Q1 '21: -221.6M Q2 '21: -233.1M Q3 '21: -237.4M Q4 '21: -242.5M Q1 '22: -247.1M Q2 '22: -255.6M Q3 '22: -272.9M Q4 '22: -293.6M Q1 '23: -314.3M Q2 '23: -330.5M Q3 '23: -348.6M Q4 '23: -380.5M Q1 '24: -454.2M Q2 '24: -530.3M Q3 '24: -548.1M Q4 '24: -497.9M Q1 '25: -425.1M Q2 '25: -309.8M Q3 '25: -307.5M Q4 '25: -300.1M Q1 '26: -313.5M Q2 '26: -322.6M Q1 '17 Q2 '18 Q3 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q1 '16: -33.8M Q2 '16: -16.9M Q3 '16: -29.2M Q4 '16: -26.4M Q1 '17: -30.7M Q2 '17: -36.1M Q3 '17: -30.5M Q4 '17: -31.2M Q1 '18: -31.5M Q2 '18: -29.6M Q3 '18: -29.8M Q4 '18: -32.8M Q1 '19: -41.5M Q2 '19: -54.8M Q3 '19: -67.7M Q4 '19: -83.9M Q3 '20: -170.9M Q4 '20: -202.2M Q1 '21: -218.7M Q2 '21: -231.3M Q3 '21: -236.4M Q4 '21: -241.8M Q1 '22: -246.8M Q2 '22: -255.9M Q3 '22: -274M Q4 '22: -295.4M Q1 '23: -314.7M Q2 '23: -329.8M Q3 '23: -347.3M Q4 '23: -373.6M Q1 '24: -444.3M Q2 '24: -510.4M Q3 '24: -518.7M Q4 '24: -465.9M Q1 '25: -391.6M Q2 '25: -281.9M Q3 '25: -289.1M Q4 '25: -288.3M Q1 '26: -309.4M Q2 '26: -325.1M Q1 '17 Q2 '18 Q3 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 40M 80M 120M Q4 '23: 0 Q1 '24: 0 Q2 '24: 636K Q3 '24: 2.8M Q4 '24: 6.2M Q1 '25: 10.7M Q2 '25: 19.2M Q3 '25: 35.1M Q4 '25: 56.1M Q1 '26: 78.5M Q2 '26: 109.4M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -29.6M Q4 '16: -33.8M Q1 '17: -37.1M Q2 '17: -25.9M Q3 '17: -21.7M Q4 '17: -22.3M Q1 '18: -27.2M Q2 '18: -24.9M Q3 '18: -25.2M Q4 '18: -25.5M Q1 '19: -23.3M Q2 '19: -29.5M Q3 '19: -35.6M Q4 '19: -41.6M Q1 '20: -65.7M Q2 '20: -78.4M Q3 '20: -114.9M Q4 '20: -157.6M Q1 '21: -170.5M Q2 '21: -193.1M Q3 '21: -190.8M Q4 '21: -183.9M Q1 '22: -190.4M Q2 '22: -200.9M Q3 '22: -214.4M Q4 '22: -224.9M Q1 '23: -259M Q2 '23: -277M Q3 '23: -302.8M Q4 '23: -324.2M Q1 '24: -389.3M Q2 '24: -449M Q3 '24: -431M Q4 '24: -455.6M Q1 '25: -395.3M Q2 '25: -307.4M Q3 '25: -160.6M Q4 '25: -189.6M Q1 '26: -268.1M Q2 '26: -197.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q1 '14: -76M Q2 '14: -76.6M Q3 '14: -78.6M Q4 '14: -79.1M Q3 '17: -21.8M Q4 '17: -22.4M Q1 '18: -27.3M Q2 '18: -24.9M Q3 '18: -25.2M Q4 '18: -25.5M Q1 '19: -23.4M Q2 '19: -29.6M Q3 '19: -35.7M Q4 '19: -41.8M Q1 '20: -66.1M Q2 '20: -78.8M Q3 '20: -115.4M Q4 '20: -157.9M Q1 '21: -170.5M Q2 '21: -193.2M Q3 '21: -190.9M Q4 '21: -184.1M Q1 '22: -190.6M Q2 '22: -201.2M Q3 '22: -214.7M Q4 '22: -225.1M Q1 '23: -259.2M Q2 '23: -277.1M Q3 '23: -303.3M Q4 '23: -325.7M Q1 '24: -391.1M Q2 '24: -450.8M Q3 '24: -433.3M Q4 '24: -457M Q1 '25: -396.4M Q2 '25: -308.4M Q3 '25: -161.6M Q4 '25: -190M Q1 '26: -272.4M Q2 '26: -206.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '10: 40.3M Q3 '10: 40.4M Q1 '11: 42M Q2 '11: 42.2M Q3 '11: 42.2M Q1 '12: 56.4M Q1 '21: 16.6M Q2 '21: 16.6M Q3 '21: 16.6M Q4 '21: 17.1M Q1 '22: 17.1M Q2 '22: 17.1M Q3 '22: 17.1M Q4 '22: 17.2M Q1 '23: 18.2M Q2 '23: 18.3M Q3 '23: 18.5M Q4 '23: 19.8M Q1 '24: 20M Q2 '24: 21.4M Q3 '24: 21.7M Q1 '25: 28.1M Q2 '25: 28.2M Q3 '25: 28.5M Q1 '26: 29M Q2 '26: 29.1M Q3 '10 Q1 '12 Q4 '21 Q4 '22 Q4 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q1 '16: -20.41 Q2 '16: -36.59 Q3 '16: -27.72 Q4 '16: -5.07 Q1 '17: 4.15 Q2 '17: 19.79 Q3 '17: 20.70 Q4 '17: -2.54 Q1 '18: -2.49 Q2 '18: -2.25 Q3 '18: -2.13 Q4 '18: -2.21 Q1 '19: -2.74 Q2 '19: -3.57 Q3 '19: -4.40 Q4 '19: -5.45 Q3 '20: -11.07 Q4 '20: -13.09 Q1 '21: -14.07 Q2 '21: -14.61 Q3 '21: -14.65 Q4 '21: -14.61 Q1 '22: -14.65 Q2 '22: -15.07 Q3 '22: -16.03 Q4 '22: -17.23 Q1 '23: -18.10 Q2 '23: -18.65 Q3 '23: -19.24 Q4 '23: -19.94 Q1 '24: -23.09 Q2 '24: -25.50 Q3 '24: -25.08 Q4 '24: -21.99 Q1 '25: -17.22 Q2 '25: -11.62 Q3 '25: -10.71 Q4 '25: -12.85 Q1 '26: -13.49 Q2 '26: -13.98 Q1 '17 Q2 '18 Q3 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.